{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:44Z","timestamp":1792093784618,"version":"4.4.0"},"reference-count":33,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Recordati"},{"name":"Recordati"},{"name":"Mudskipper Business Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (GH) and overproduction of insulin-like growth factor I (IGF-I). Medical therapies, including the somatostatin receptor ligand (SRL) pasireotide, are frequently used to restore biochemical control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>As patients often receive therapy over prolonged periods, long-term data from real-life settings are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was performed using a prospectively maintained database of all patients with acromegaly from our primary care center who were enrolled in clinical studies with pasireotide (first visit November 2008). The main outcome measures were safety and biochemical control (age-adjusted IGF-I \u2264 upper limit of normal).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients (n = 50) entered 4 parental studies and 30 continued in the rollover; at data cutoff (June 2022), 27 were still receiving pasireotide. Overall, median (range) exposure was 58 (3-137) months. Normal IGF-I was achieved in 54%, and acromegaly symptoms and quality of life were improved with treatment. No predictors of pasireotide response were identified; however, controlled patients had smaller tumors and lower GH at baseline. Tumor volume reduction occurred in 63% of evaluable patients (n = 10\/16). Most patients presented hyperglycemic events, including 63.2% of patients with normal glucose before treatment. Older patients and those with higher IGF-I, glucose, and HbA1c at baseline had higher glucose and HbA1c during pasireotide treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pasireotide provided clinical benefit and was well tolerated for more than 11 years of treatment in acromegaly patients, most of whom were resistant to first-generation SRLs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad378","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T06:05:46Z","timestamp":1687759546000},"page":"e1571-e1579","source":"Crossref","is-referenced-by-count":35,"title":["Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"M\u00f4nica","family":"Gadelha","sequence":"first","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelma Ver\u00f4nica","family":"Marques","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christhiane","family":"Fialho","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane","family":"Scaf","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lamback","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximene","family":"Antunes","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Santos","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"issue":"7","key":"2023111712401909500_dgad378-B1","first-page":"411","article-title":"Acromegaly","volume":"110","author":"Dineen","year":"2017","journal-title":"QJM"},{"issue":"1","key":"2023111712401909500_dgad378-B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1042-3680(02)00035-9","article-title":"Pathology of pituitary tumors","volume":"14","author":"Sanno","year":"2003","journal-title":"Neurosurg Clin N Am"},{"issue":"1","key":"2023111712401909500_dgad378-B3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"2023111712401909500_dgad378-B4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-1022","article-title":"Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy)","volume":"171","author":"Colao","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2023111712401909500_dgad378-B5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fendo.2017.00040","article-title":"Predictors of quality of life in acromegaly: no consensus on biochemical parameters","volume":"8","author":"Geraedts","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2023111712401909500_dgad378-B6","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023111712401909500_dgad378-B7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2023111712401909500_dgad378-B8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2023111712401909500_dgad378-B9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2023111712401909500_dgad378-B10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"2023111712401909500_dgad378-B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023111712401909500_dgad378-B12","author":"Recordati AG"},{"key":"2023111712401909500_dgad378-B13","author":"Recordati AG"},{"issue":"9","key":"2023111712401909500_dgad378-B14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-015-0413-y","article-title":"Pasireotide in acromegaly: a review","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"issue":"5","key":"2023111712401909500_dgad378-B15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023111712401909500_dgad378-B16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023111712401909500_dgad378-B17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023111712401909500_dgad378-B18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"key":"2023111712401909500_dgad378-B19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"2023111712401909500_dgad378-B20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2023111712401909500_dgad378-B21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"2023111712401909500_dgad378-B22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-2-13","article-title":"Acromegaly quality of life questionnaire (AcroQoL)","volume":"2","author":"Badia","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2023111712401909500_dgad378-B23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","article-title":"Long-term safety and efficacy of long-acting pasireotide in acromegaly","volume":"74","author":"Akirov","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"2023111712401909500_dgad378-B24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2023111712401909500_dgad378-B25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2023111712401909500_dgad378-B26","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"issue":"12","key":"2023111712401909500_dgad378-B27","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0296","article-title":"Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR","volume":"11","author":"Wolf","year":"2022","journal-title":"Endocr Connect"},{"issue":"8","key":"2023111712401909500_dgad378-B28","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023111712401909500_dgad378-B29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jcph.213","article-title":"Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, phase I, randomized, four-way crossover study","volume":"54","author":"Breitschaft","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2023111712401909500_dgad378-B30","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023111712401909500_dgad378-B31","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023111712401909500_dgad378-B32","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101679","article-title":"Innovative therapeutics in acromegaly","volume":"36","author":"Kasuki","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2023111712401909500_dgad378-B33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad378\/50837100\/dgad378.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/e1571\/53480903\/dgad378.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/e1571\/53480903\/dgad378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T08:41:40Z","timestamp":1700210500000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/12\/e1571\/7207510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6,26]]},"published-print":{"date-parts":[[2023,11,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad378","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,6,26]]}}}